Zura Bio Limited (ZURA)
Nasdaq · Healthcare · Biotechnology
$3.93−4.38%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $377M
- 52-week range
- $3.15 – $7.44
- 52-week change
- −1.44%
- EPS (trailing)
- −$1.12
- Analyst rating
- 1.1 Strong buy
- Next earnings
- Nov 12, 2026
Fiscal year to Dec 2025
- Net income
- −$68.7M
- Diluted EPS
- −$1.06
- Free cash flow
- −$64.9M
From the company’s annual report on SEC EDGAR.
About Zura Bio Limited
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880), a fully human immunoglobulin G4 monoclonal antibody targeting interleukin-33 that has completed Phase 1 clinical studies; and Crebankitug (ZB-168), a fully human immunoglobulin G1 monoclonal antibody targeting interleukin-7 receptor alpha that has completed Phase 1 clinical studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada.
Headquarters: Henderson, United States · 40 employees · zurabio.com